You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePiretanide
Accession NumberDB02925  (EXPT03308)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArelixNot Available
PiretanideJAN
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIDQ6KK6GV93
CAS number55837-27-9
WeightAverage: 362.4
Monoisotopic: 362.093642386
Chemical FormulaC17H18N2O5S
InChI KeyInChIKey=UJEWTUDSLQGTOA-UHFFFAOYSA-N
InChI
InChI=1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)
IUPAC Name
4-phenoxy-3-(pyrrolidin-1-yl)-5-sulfamoylbenzoic acid
SMILES
NS(=O)(=O)C1=CC(=CC(N2CCCC2)=C1OC1=CC=CC=C1)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylethers
Direct ParentDiphenylethers
Alternative Parents
Substituents
  • Diphenylether
  • 1-phenylpyrrolidine
  • Diaryl ether
  • Aminobenzenesulfonamide
  • Benzenesulfonamide
  • Aminobenzoic acid or derivatives
  • Aminobenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Substituted aniline
  • Dialkylarylamine
  • Benzoyl
  • Aniline
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Pyrrolidine
  • Pyrrole
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9907
Blood Brain Barrier+0.6318
Caco-2 permeable-0.6466
P-glycoprotein substrateNon-substrate0.5237
P-glycoprotein inhibitor INon-inhibitor0.8026
P-glycoprotein inhibitor IINon-inhibitor0.6635
Renal organic cation transporterNon-inhibitor0.7657
CYP450 2C9 substrateNon-substrate0.7067
CYP450 2D6 substrateNon-substrate0.8032
CYP450 3A4 substrateNon-substrate0.5997
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6747
Ames testNon AMES toxic0.6433
CarcinogenicityNon-carcinogens0.6985
BiodegradationNot ready biodegradable0.9786
Rat acute toxicity1.8427 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.848
hERG inhibition (predictor II)Inhibitor0.5391
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.92BIOBYTE (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0914 mg/mLALOGPS
logP2.2ALOGPS
logP2.25ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)4.68ChemAxon
pKa (Strongest Basic)-0.62ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.93 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity93.68 m3·mol-1ChemAxon
Polarizability35.85 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Yuji Chikaraishi, Yoshihisa Matsuda, Makoto Otsuka, “Amorphous piretanide, piretanide polymorphs, process for their preparation and their use.” U.S. Patent US6096779, issued September, 1993.

US6096779
General ReferencesNot Available
External Links
ATC CodesC03CA03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Piretanide.
AceclofenacAceclofenac may decrease the diuretic activities of Piretanide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Piretanide.
AdapaleneAdapalene may decrease the diuretic activities of Piretanide.
AlclometasoneAlclometasone may increase the hypokalemic activities of Piretanide.
AldosteroneAldosterone may increase the hypokalemic activities of Piretanide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Piretanide.
AllopurinolThe risk or severity of adverse effects can be increased when Piretanide is combined with Allopurinol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Piretanide.
AmcinonideAmcinonide may increase the hypokalemic activities of Piretanide.
AmikacinThe risk or severity of adverse effects can be increased when Piretanide is combined with Amikacin.
Aminosalicylic AcidAminosalicylic Acid may decrease the diuretic activities of Piretanide.
AntipyrineAntipyrine may decrease the diuretic activities of Piretanide.
ApremilastApremilast may decrease the diuretic activities of Piretanide.
ArbutamineArbutamine may increase the hypokalemic activities of Piretanide.
ArformoterolArformoterol may increase the hypokalemic activities of Piretanide.
AzapropazoneAzapropazone may decrease the diuretic activities of Piretanide.
AzelastineAzelastine may decrease the diuretic activities of Piretanide.
BalsalazideBalsalazide may decrease the diuretic activities of Piretanide.
BambuterolBambuterol may increase the hypokalemic activities of Piretanide.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Piretanide.
BenazeprilPiretanide may increase the hypotensive activities of Benazepril.
BenoxaprofenBenoxaprofen may decrease the diuretic activities of Piretanide.
BetamethasoneBetamethasone may increase the hypokalemic activities of Piretanide.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Piretanide.
BromfenacBromfenac may decrease the diuretic activities of Piretanide.
BudesonideBudesonide may increase the hypokalemic activities of Piretanide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Piretanide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Piretanide.
CanagliflozinCanagliflozin may increase the hypotensive activities of Piretanide.
CandoxatrilPiretanide may increase the hypotensive activities of Candoxatril.
CaptoprilPiretanide may increase the hypotensive activities of Captopril.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Piretanide.
CarprofenCarprofen may decrease the diuretic activities of Piretanide.
CastanospermineCastanospermine may decrease the diuretic activities of Piretanide.
CelecoxibCelecoxib may decrease the diuretic activities of Piretanide.
CeliprololCeliprolol may increase the hypokalemic activities of Piretanide.
ChloroquineChloroquine may decrease the diuretic activities of Piretanide.
CholestyramineCholestyramine can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideCiclesonide may increase the hypokalemic activities of Piretanide.
CilazaprilPiretanide may increase the hypotensive activities of Cilazapril.
CisplatinPiretanide may increase the nephrotoxic activities of Cisplatin.
ClenbuterolClenbuterol may increase the hypokalemic activities of Piretanide.
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Piretanide.
ClocortoloneClocortolone may increase the hypokalemic activities of Piretanide.
ClonixinClonixin may decrease the diuretic activities of Piretanide.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Piretanide.
ColesevelamColesevelam can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Piretanide.
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Piretanide.
D-LimoneneD-Limonene may decrease the diuretic activities of Piretanide.
DaunorubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Daunorubicin.
DehydroepiandrosteroneDehydroepiandrosterone may increase the hypokalemic activities of Piretanide.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Piretanide.
DeslanosideThe risk or severity of adverse effects can be increased when Piretanide is combined with Deslanoside.
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Piretanide.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Piretanide.
DexamethasoneDexamethasone may increase the hypokalemic activities of Piretanide.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Piretanide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Piretanide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Piretanide.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Piretanide.
DiclofenacDiclofenac may decrease the diuretic activities of Piretanide.
DiflorasoneDiflorasone may increase the hypokalemic activities of Piretanide.
DiflunisalDiflunisal may decrease the diuretic activities of Piretanide.
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Piretanide.
DifluprednateDifluprednate may increase the hypokalemic activities of Piretanide.
DigitoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Piretanide.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Piretanide.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Piretanide.
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Dihydrostreptomycin.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Piretanide.
DipivefrinDipivefrin may increase the hypokalemic activities of Piretanide.
DobutamineDobutamine may increase the hypokalemic activities of Piretanide.
DofetilidePiretanide may increase the QTc-prolonging activities of Dofetilide.
DoxorubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Doxorubicin.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Piretanide.
DroxicamDroxicam may decrease the diuretic activities of Piretanide.
DroxidopaDroxidopa may increase the hypokalemic activities of Piretanide.
EnalaprilPiretanide may increase the hypotensive activities of Enalapril.
EnalaprilatPiretanide may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the hypokalemic activities of Piretanide.
EpinephrineEpinephrine may increase the hypokalemic activities of Piretanide.
EpirizoleEpirizole may decrease the diuretic activities of Piretanide.
EpirubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Epirubicin.
EquileninEquilenin may increase the hypokalemic activities of Piretanide.
EquilinEquilin may increase the hypokalemic activities of Piretanide.
EstroneEstrone may increase the hypokalemic activities of Piretanide.
EtanerceptEtanercept may decrease the diuretic activities of Piretanide.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Piretanide.
EtodolacEtodolac may decrease the diuretic activities of Piretanide.
EtofenamateEtofenamate may decrease the diuretic activities of Piretanide.
EtoricoxibEtoricoxib may decrease the diuretic activities of Piretanide.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Piretanide.
Evening primrose oilEvening primrose oil may decrease the diuretic activities of Piretanide.
exisulindexisulind may decrease the diuretic activities of Piretanide.
FenbufenFenbufen may decrease the diuretic activities of Piretanide.
FenoprofenFenoprofen may decrease the diuretic activities of Piretanide.
FenoterolFenoterol may increase the hypokalemic activities of Piretanide.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Piretanide.
FloctafenineFloctafenine may decrease the diuretic activities of Piretanide.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Piretanide.
FlumethasoneFlumethasone may increase the hypokalemic activities of Piretanide.
FlunisolideFlunisolide may increase the hypokalemic activities of Piretanide.
FlunixinFlunixin may decrease the diuretic activities of Piretanide.
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Piretanide.
FluocinonideFluocinonide may increase the hypokalemic activities of Piretanide.
FluocortoloneFluocortolone may increase the hypokalemic activities of Piretanide.
FluorometholoneFluorometholone may increase the hypokalemic activities of Piretanide.
FluprednideneFluprednidene may increase the hypokalemic activities of Piretanide.
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Piretanide.
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Piretanide.
FlurbiprofenFlurbiprofen may decrease the diuretic activities of Piretanide.
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Piretanide.
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Piretanide.
FormoterolFormoterol may increase the hypokalemic activities of Piretanide.
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Piretanide.
FosinoprilPiretanide may increase the hypotensive activities of Fosinopril.
FosphenytoinFosphenytoin may decrease the diuretic activities of Piretanide.
FramycetinThe risk or severity of adverse effects can be increased when Piretanide is combined with Framycetin.
GentamicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Gentamicin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Piretanide.
HMPL-004HMPL-004 may decrease the diuretic activities of Piretanide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Piretanide.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Piretanide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Piretanide.
Hygromycin BThe risk or severity of adverse effects can be increased when Piretanide is combined with Hygromycin B.
IbuprofenIbuprofen may decrease the diuretic activities of Piretanide.
IbuproxamIbuproxam may decrease the diuretic activities of Piretanide.
IcatibantIcatibant may decrease the diuretic activities of Piretanide.
IdarubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Idarubicin.
IndacaterolIndacaterol may increase the hypokalemic activities of Piretanide.
IndomethacinIndomethacin may decrease the diuretic activities of Piretanide.
IndoprofenIndoprofen may decrease the diuretic activities of Piretanide.
IsoetarineIsoetarine may increase the hypokalemic activities of Piretanide.
IsoprenalineIsoprenaline may increase the hypokalemic activities of Piretanide.
IsoxicamIsoxicam may decrease the diuretic activities of Piretanide.
IvabradinePiretanide may increase the arrhythmogenic activities of Ivabradine.
KanamycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Kanamycin.
KebuzoneKebuzone may decrease the diuretic activities of Piretanide.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Piretanide.
KetoprofenKetoprofen may decrease the diuretic activities of Piretanide.
KetorolacKetorolac may decrease the diuretic activities of Piretanide.
LeflunomideLeflunomide may decrease the diuretic activities of Piretanide.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Piretanide.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Piretanide.
LicoriceLicorice may increase the hypokalemic activities of Piretanide.
LisinoprilPiretanide may increase the hypotensive activities of Lisinopril.
LithiumThe serum concentration of Lithium can be decreased when it is combined with Piretanide.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Piretanide.
LornoxicamLornoxicam may decrease the diuretic activities of Piretanide.
LoxoprofenLoxoprofen may decrease the diuretic activities of Piretanide.
LumiracoxibLumiracoxib may decrease the diuretic activities of Piretanide.
Magnesium salicylateMagnesium salicylate may decrease the diuretic activities of Piretanide.
MasoprocolMasoprocol may decrease the diuretic activities of Piretanide.
Meclofenamic acidMeclofenamic acid may decrease the diuretic activities of Piretanide.
MedrysoneMedrysone may increase the hypokalemic activities of Piretanide.
Mefenamic acidMefenamic acid may decrease the diuretic activities of Piretanide.
MelengestrolMelengestrol may increase the hypokalemic activities of Piretanide.
MeloxicamMeloxicam may decrease the diuretic activities of Piretanide.
MesalazineMesalazine may decrease the diuretic activities of Piretanide.
MetamizoleMetamizole may decrease the diuretic activities of Piretanide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Piretanide.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Piretanide.
MethotrexateThe therapeutic efficacy of Piretanide can be decreased when used in combination with Methotrexate.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Piretanide.
MetrizamideThe risk or severity of adverse effects can be increased when Piretanide is combined with Metrizamide.
MoexiprilPiretanide may increase the hypotensive activities of Moexipril.
MometasoneMometasone may increase the hypokalemic activities of Piretanide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Piretanide.
Mycophenolate mofetilMycophenolate mofetil may decrease the diuretic activities of Piretanide.
Mycophenolic acidMycophenolic acid may decrease the diuretic activities of Piretanide.
NabumetoneNabumetone may decrease the diuretic activities of Piretanide.
NaftifineNaftifine may decrease the diuretic activities of Piretanide.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Piretanide.
NaproxenNaproxen may decrease the diuretic activities of Piretanide.
NCX 4016NCX 4016 may decrease the diuretic activities of Piretanide.
NeomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Neomycin.
NepafenacNepafenac may decrease the diuretic activities of Piretanide.
NetilmicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Netilmicin.
Niflumic AcidNiflumic Acid may decrease the diuretic activities of Piretanide.
NimesulideNimesulide may decrease the diuretic activities of Piretanide.
NorepinephrineNorepinephrine may increase the hypokalemic activities of Piretanide.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Piretanide.
OlodaterolOlodaterol may increase the hypokalemic activities of Piretanide.
OlopatadineOlopatadine may decrease the diuretic activities of Piretanide.
OlsalazineOlsalazine may decrease the diuretic activities of Piretanide.
OmapatrilatPiretanide may increase the hypotensive activities of Omapatrilat.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Piretanide.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Piretanide.
OrgoteinOrgotein may decrease the diuretic activities of Piretanide.
OuabainThe risk or severity of adverse effects can be increased when Piretanide is combined with Ouabain.
OxaprozinOxaprozin may decrease the diuretic activities of Piretanide.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Piretanide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Piretanide.
OxyphenbutazoneOxyphenbutazone may decrease the diuretic activities of Piretanide.
ParamethasoneParamethasone may increase the hypokalemic activities of Piretanide.
ParecoxibParecoxib may decrease the diuretic activities of Piretanide.
ParomomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Paromomycin.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Piretanide.
PerindoprilPiretanide may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Piretanide.
PhenylbutazonePhenylbutazone may decrease the diuretic activities of Piretanide.
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Piretanide.
PhenytoinPhenytoin may decrease the diuretic activities of Piretanide.
PimecrolimusPimecrolimus may decrease the diuretic activities of Piretanide.
PirbuterolPirbuterol may increase the hypokalemic activities of Piretanide.
PirfenidonePirfenidone may decrease the diuretic activities of Piretanide.
PiroxicamPiroxicam may decrease the diuretic activities of Piretanide.
PlicamycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Plicamycin.
PrednicarbatePrednicarbate may increase the hypokalemic activities of Piretanide.
PrednisolonePrednisolone may increase the hypokalemic activities of Piretanide.
PrednisonePrednisone may increase the hypokalemic activities of Piretanide.
PregnenolonePregnenolone may increase the hypokalemic activities of Piretanide.
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Piretanide.
ProcaterolProcaterol may increase the hypokalemic activities of Piretanide.
PropacetamolPropacetamol may decrease the diuretic activities of Piretanide.
PTC299PTC299 may decrease the diuretic activities of Piretanide.
PuromycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Puromycin.
QuinaprilPiretanide may increase the hypotensive activities of Quinapril.
RamiprilPiretanide may increase the hypotensive activities of Ramipril.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Piretanide.
RescinnaminePiretanide may increase the hypotensive activities of Rescinnamine.
ResveratrolResveratrol may decrease the diuretic activities of Piretanide.
RibostamycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Ribostamycin.
RimexoloneRimexolone may increase the hypokalemic activities of Piretanide.
RisperidoneThe risk or severity of adverse effects can be increased when Piretanide is combined with Risperidone.
RitodrineRitodrine may increase the hypokalemic activities of Piretanide.
RofecoxibRofecoxib may decrease the diuretic activities of Piretanide.
SalbutamolSalbutamol may increase the hypokalemic activities of Piretanide.
SalicylamideSalicylamide may decrease the diuretic activities of Piretanide.
Salicylic acidSalicylic acid may decrease the diuretic activities of Piretanide.
SalmeterolSalmeterol may increase the hypokalemic activities of Piretanide.
SalsalateSalsalate may decrease the diuretic activities of Piretanide.
SeratrodastSeratrodast may decrease the diuretic activities of Piretanide.
SpectinomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Spectinomycin.
SpiraprilPiretanide may increase the hypotensive activities of Spirapril.
SRT501SRT501 may decrease the diuretic activities of Piretanide.
StreptomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Streptomycin.
StreptozocinThe risk or severity of adverse effects can be increased when Piretanide is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Piretanide.
SulfasalazineSulfasalazine may decrease the diuretic activities of Piretanide.
SulindacSulindac may decrease the diuretic activities of Piretanide.
SulpirideThe risk or severity of adverse effects can be increased when Piretanide is combined with Sulpiride.
SuprofenSuprofen may decrease the diuretic activities of Piretanide.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Piretanide.
TemocaprilPiretanide may increase the hypotensive activities of Temocapril.
TenoxicamTenoxicam may decrease the diuretic activities of Piretanide.
TepoxalinTepoxalin may decrease the diuretic activities of Piretanide.
TerbutalineTerbutaline may increase the hypokalemic activities of Piretanide.
TeriflunomideTeriflunomide may decrease the diuretic activities of Piretanide.
Tiaprofenic acidTiaprofenic acid may decrease the diuretic activities of Piretanide.
TixocortolTixocortol may increase the hypokalemic activities of Piretanide.
TobramycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Tobramycin.
Tolfenamic AcidTolfenamic Acid may decrease the diuretic activities of Piretanide.
TolmetinTolmetin may decrease the diuretic activities of Piretanide.
TopiramatePiretanide may increase the hypokalemic activities of Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Piretanide.
TrandolaprilPiretanide may increase the hypotensive activities of Trandolapril.
TranilastTranilast may decrease the diuretic activities of Piretanide.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Piretanide.
Trisalicylate-cholineTrisalicylate-choline may decrease the diuretic activities of Piretanide.
ValdecoxibValdecoxib may decrease the diuretic activities of Piretanide.
VilanterolVilanterol may increase the hypokalemic activities of Piretanide.
ZaltoprofenZaltoprofen may decrease the diuretic activities of Piretanide.
ZileutonZileuton may decrease the diuretic activities of Piretanide.
ZomepiracZomepirac may decrease the diuretic activities of Piretanide.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23